MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.
Federica RinaldiFrancesco MarchesiFrancesca PalombiAndrea PelosiAnna Laura Di PaceAndrea SacconiIrene TerrenatoOmbretta AnnibaliValeria TomarchioMirella MarinoMaria CantonettiSara VaccariniElena PapaLorenzo MorettaFrancesco BertoniAndrea MengarelliGiulia RegazzoMaria G RizzoPublished in: British journal of haematology (2021)
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, heterogeneous neoplasm where prognostication and therapeutic decision are challenging. The available prognostic tools are not able to identify all patients refractory to treatment. MicroRNAs, small RNAs frequently deregulated in cancer, stably circulate in biofluids, representing interesting candidates for non-invasive biomarkers. Here we validated serum miR-22, an evolutionarily conserved microRNA, as a prognostic/predictive biomarker in DLBCL. Moreover, we found that its expression and release from DLBCL cells are related to therapy response and adversely affect cell proliferation. These results suggest that miR-22 is a promising complementary or even independent non-invasive biomarker for DLBCL management.
Keyphrases
- diffuse large b cell lymphoma
- cell proliferation
- epstein barr virus
- end stage renal disease
- long non coding rna
- newly diagnosed
- chronic kidney disease
- prognostic factors
- poor prognosis
- long noncoding rna
- cell cycle
- transcription factor
- decision making
- young adults
- low grade
- binding protein
- endoplasmic reticulum stress
- smoking cessation